Product Images Irbesartan And Hydrochlorothiazide

The text describes a study on the efficacy of Irbesartan, Hydrochlorothiazide, and a combination of both drugs in achieving a systolic blood pressure lower than 140 mmHg. The study is divided into two groups, Study V and Study VI, with different durations of therapy. The text includes a graph showing the probability of achieving the desired blood pressure level at different baseline levels.*

This appears to be a graph that shows the probability of patients achieving SBP (systolic blood pressure) below 130 mmHg in two medication studies (Study V and Study VI) at different baseline SBP levels. The medication used in the studies was Irbesartan and Hydrochlorothiazide.*

This text represents a figure (Figure 2a) that shows the probability of achieving a Diastolic Blood Pressure (DBP) lower than 90 mmHg in patients from different studies involving irbesartan and hydrochlorothiazide, after a certain number of weeks (Week 7 and Week 8). It seems to be related to the effectiveness of the drugs in lowering blood pressure, but a complete description cannot be provided without analyzing the details of the figure.*

This is a description of a study comparing the effectiveness of two drugs, Irbesartan and hydrochlorothiazide, in lowering diastolic blood pressure (DBP) in patients. The study is divided into two parts, Study V and Study VI, and the results are displayed in a graph that shows the probability of patients achieving a DBP of less than 80 mmHg after taking each drug for several weeks. The number of patients who achieved this goal is also listed in the text.*

The text provides a figure illustrating the placebo-subtracted reduction in trough SeSBP (systolic blood pressure) for different doses (in mg/day) of Irbesartan. The doses are listed as 150, 300, 450, 600, 750, and 900. There is no further context or information provided.*

The text describes a chart or figure showing the dose of Irbesartan (a medication) in mg/day and the reduction in trough SeDBP (systolic blood pressure) in comparison with a placebo. It appears to be part of an integrated analysis.*

Each film-coated tablet contains 150 mg of Irbesartan USP and 12.5 mg of hydrochlorothiazide USP, distributed by Aurobindo Pharma USA, Inc. The tablets are packaged in a bottle containing 30 tablets and are meant for prescription use only. The recommended storage temperature is between 20° to 25°C (68° to 77°F). The product is made in India and the code on the package is TS/DRUES/22/2009.*

This is a description of a medication, containing irbesartan USP 300 mg and hydrochlorothiazide USP 2.5 mg, packaged in 30 tablets with controlled room temperature. The medication is distributed by Aurobindo Pharma USA, Inc. with the code TS/DRUGS/22/2009 and is Rx only. The package insert contains the necessary dosage instructions. The medication is stored at 20° to 25°C (68° to 77°F) and caution should be taken not to print on the dotted lines in the overprinting zone. The manufacturer of the medication is located in India.*

This is a description of a medication called Irbesartan and Hydrochlorothiazide. Each film-coated tablet contains 25 mg of hydrochlorothiazide USP and 300 mg of Irbesartan. This medication is distributed by Aurobindo Pharma USA, Inc. and is only available with a prescription. The user is directed to see the package insert for dosing information. The tablets should be stored at a controlled room temperature between 20° to 25°C (68° to 77°F). There is also some printing and coding information included.*